Mindfulness Based Stress Reduction in COPD

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Roberto P. Benzo, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01058499
First received: January 27, 2010
Last updated: April 18, 2012
Last verified: April 2012
  Purpose

The objective of this study is to test the efficacy of a Mindfulness Based Stress Reduction program in COPD on quality of life, dyspnea, daily physical activity and mindfulness during daily life.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
COPD
Behavioral: Mindfulness Based Stress Reduction Program (MBSR)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Mindfulness Based Stress Reduction in COPD

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • We hypothesize that the perception of well being will increase after participants go through the MBSR program for COPD. [ Time Frame: Baseline and at eight weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Participants in the MBSR for COPD will have an increase in their physical activity level. [ Time Frame: Baseline and 8 weeks ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: February 2010
Study Completion Date: December 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MBSR Behavioral: Mindfulness Based Stress Reduction Program (MBSR)
Traditional eight-week MBSR Program.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • clinical diagnosis of COPD
  • clinically significant dyspnea, as determined by a score of >=2 on the Medical Research Council of Dyspnea Score questionnaire (0-4).

Exclusion criteria:

  • patients with a high likelihood of not completing the program (active chemical dependency)
  • patients with an inability fo provide good data or to follow commands (neurologic or psychiatric condition).
  • poor motivation or lack of interest in program
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01058499

Locations
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Roberto Benzo, MD Mayo Clinic
  More Information

No publications provided

Responsible Party: Roberto P. Benzo, M.D., Mayo Clinic
ClinicalTrials.gov Identifier: NCT01058499     History of Changes
Other Study ID Numbers: 09-008478
Study First Received: January 27, 2010
Last Updated: April 18, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
Chronic Obstructive Pulmonary Disease
COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on September 18, 2014